US5378696A
(en)
*
|
1990-09-19 |
1995-01-03 |
American Home Products Corporation |
Rapamycin esters
|
US5177203A
(en)
*
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5480989A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480988A
(en)
*
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5489680A
(en)
*
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5434260A
(en)
*
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5258389A
(en)
*
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
US5349060A
(en)
*
|
1993-01-07 |
1994-09-20 |
American Home Products Corporation |
Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
|
US5252579A
(en)
*
|
1993-02-16 |
1993-10-12 |
American Home Products Corporation |
Macrocyclic immunomodulators
|
US5310901A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
|
US5310903A
(en)
*
|
1993-03-05 |
1994-05-10 |
Merck & Co., Inc. |
Imidazolidyl rapamycin derivatives
|
GB9307491D0
(en)
*
|
1993-04-08 |
1993-06-02 |
Sandoz Ltd |
Organic compounds
|
US5504091A
(en)
*
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
US7279561B1
(en)
*
|
1993-04-23 |
2007-10-09 |
Wyeth |
Anti-rapamycin monoclonal antibodies
|
AU686629B2
(en)
|
1993-04-23 |
1998-02-12 |
Wyeth |
Rapamycin Conjugates and Antibodies
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
US5387680A
(en)
*
|
1993-08-10 |
1995-02-07 |
American Home Products Corporation |
C-22 ring stabilized rapamycin derivatives
|
US5391730A
(en)
*
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
US5378836A
(en)
*
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
US5373014A
(en)
*
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
US5527907A
(en)
*
|
1993-11-19 |
1996-06-18 |
Abbott Laboratories |
Macrolide immunomodulators
|
CA2175215C
(en)
*
|
1993-11-19 |
2008-06-03 |
Yat Sun Or |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
US5385909A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
US5385910A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
US5385908A
(en)
*
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
CN1046944C
(zh)
*
|
1993-12-17 |
1999-12-01 |
山道士有限公司 |
雷怕霉素类衍生物
|
US5389639A
(en)
*
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
US5525610A
(en)
*
|
1994-03-31 |
1996-06-11 |
American Home Products Corporation |
42-Epi-rapamycin and pharmaceutical compositions thereof
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US5463048A
(en)
*
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
IL115742A
(en)
|
1994-10-26 |
2000-06-01 |
Novartis Ag |
Pharmaceutical compositions comprising a difficultly soluble active agent a hydrophilic phase a lipophilic phase and a surfactant
|
US5491231A
(en)
*
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5621108A
(en)
*
|
1994-12-05 |
1997-04-15 |
Trustees Of The University Of Pennsylvania |
Processes and intermediates for preparing macrocycles
|
US5563145A
(en)
*
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
RU2158267C2
(ru)
|
1995-06-09 |
2000-10-27 |
Новартис Аг |
Производные рапамицина и фармацевтическая композиция на их основе
|
US5780462A
(en)
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
US5922730A
(en)
*
|
1996-09-09 |
1999-07-13 |
American Home Products Corporation |
Alkylated rapamycin derivatives
|
US20060198867A1
(en)
*
|
1997-09-25 |
2006-09-07 |
Abbott Laboratories, Inc. |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
US6890546B2
(en)
|
1998-09-24 |
2005-05-10 |
Abbott Laboratories |
Medical devices containing rapamycin analogs
|
US20030129215A1
(en)
|
1998-09-24 |
2003-07-10 |
T-Ram, Inc. |
Medical devices containing rapamycin analogs
|
US7399480B2
(en)
|
1997-09-26 |
2008-07-15 |
Abbott Laboratories |
Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
|
US6015815A
(en)
|
1997-09-26 |
2000-01-18 |
Abbott Laboratories |
Tetrazole-containing rapamycin analogs with shortened half-lives
|
US8394398B2
(en)
*
|
1997-09-26 |
2013-03-12 |
Abbott Laboratories |
Methods of administering rapamycin analogs with anti-inflammatories using medical devices
|
US7378105B2
(en)
*
|
1997-09-26 |
2008-05-27 |
Abbott Laboratories |
Drug delivery systems, kits, and methods for administering zotarolimus and paclitaxel to blood vessel lumens
|
US7357942B2
(en)
*
|
1997-09-26 |
2008-04-15 |
Abbott Laboratories |
Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
|
US8057816B2
(en)
*
|
1997-09-26 |
2011-11-15 |
Abbott Laboratories |
Compositions and methods of administering paclitaxel with other drugs using medical devices
|
US8257726B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
|
US8257725B2
(en)
*
|
1997-09-26 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
US20030216303A1
(en)
*
|
1998-03-06 |
2003-11-20 |
Michael Ambuhl |
Emulsion preconcentrates containing cyclosporin or a macrolide
|
US6015809A
(en)
*
|
1998-08-17 |
2000-01-18 |
American Home Products Corporation |
Photocyclized rapamycin
|
US7960405B2
(en)
*
|
1998-09-24 |
2011-06-14 |
Abbott Laboratories |
Compounds and methods for treatment and prevention of diseases
|
US7455853B2
(en)
*
|
1998-09-24 |
2008-11-25 |
Abbott Cardiovascular Systems Inc. |
Medical devices containing rapamycin analogs
|
US20060240070A1
(en)
*
|
1998-09-24 |
2006-10-26 |
Cromack Keith R |
Delivery of highly lipophilic agents via medical devices
|
US8257724B2
(en)
*
|
1998-09-24 |
2012-09-04 |
Abbott Laboratories |
Delivery of highly lipophilic agents via medical devices
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US6331547B1
(en)
|
1999-08-18 |
2001-12-18 |
American Home Products Corporation |
Water soluble SDZ RAD esters
|
US6790228B2
(en)
*
|
1999-12-23 |
2004-09-14 |
Advanced Cardiovascular Systems, Inc. |
Coating for implantable devices and a method of forming the same
|
US7807211B2
(en)
|
1999-09-03 |
2010-10-05 |
Advanced Cardiovascular Systems, Inc. |
Thermal treatment of an implantable medical device
|
US20070032853A1
(en)
*
|
2002-03-27 |
2007-02-08 |
Hossainy Syed F |
40-O-(2-hydroxy)ethyl-rapamycin coated stent
|
US6277983B1
(en)
|
2000-09-27 |
2001-08-21 |
American Home Products Corporation |
Regioselective synthesis of rapamycin derivatives
|
TWI256395B
(en)
*
|
1999-09-29 |
2006-06-11 |
Wyeth Corp |
Regioselective synthesis of rapamycin derivatives
|
GB0008785D0
(en)
|
2000-04-10 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
US6670355B2
(en)
|
2000-06-16 |
2003-12-30 |
Wyeth |
Method of treating cardiovascular disease
|
EP1318837B1
(en)
|
2000-08-11 |
2004-10-06 |
Wyeth |
Method of treating estrogen receptor positive carcinoma
|
DE60136200D1
(de)
|
2000-09-19 |
2008-11-27 |
Wyeth Corp |
Wasserlösliche rapamycin-ester
|
US6399625B1
(en)
|
2000-09-27 |
2002-06-04 |
Wyeth |
1-oxorapamycins
|
US6440991B1
(en)
|
2000-10-02 |
2002-08-27 |
Wyeth |
Ethers of 7-desmethlrapamycin
|
US6399626B1
(en)
|
2000-10-02 |
2002-06-04 |
Wyeth |
Hydroxyesters of 7-desmethylrapamycin
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20080145402A1
(en)
*
|
2001-09-10 |
2008-06-19 |
Abbott Cardiovascular Systems Inc. |
Medical Devices Containing Rapamycin Analogs
|
US6939376B2
(en)
*
|
2001-11-05 |
2005-09-06 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
US7682387B2
(en)
*
|
2002-04-24 |
2010-03-23 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
PT1478358E
(pt)
|
2002-02-11 |
2013-09-11 |
Bayer Healthcare Llc |
Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
|
US20040024450A1
(en)
*
|
2002-04-24 |
2004-02-05 |
Sun Biomedical, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
CA2493878C
(en)
|
2002-07-30 |
2013-07-23 |
Wyeth |
Parenteral formulations containing a rapamycin hydroxyester
|
NZ538568A
(en)
*
|
2002-09-06 |
2010-09-30 |
Abbott Lab |
Medical device having hydration inhibitor
|
WO2004060283A2
(en)
*
|
2002-12-16 |
2004-07-22 |
Nitromed, Inc. |
Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
|
WO2004069159A2
(en)
*
|
2003-01-27 |
2004-08-19 |
Endocyte, Inc. |
Vitamin receptor binding drug delivery conjugates
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
JP2007511203A
(ja)
|
2003-05-20 |
2007-05-10 |
バイエル、ファーマシューテイカルズ、コーポレイション |
キナーゼ阻害活性を有するジアリール尿素
|
US20050118344A1
(en)
|
2003-12-01 |
2005-06-02 |
Pacetti Stephen D. |
Temperature controlled crimping
|
DE602004010407T2
(de)
*
|
2003-07-23 |
2008-10-16 |
Bayer Pharmaceuticals Corp., West Haven |
Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
|
CN102144961A
(zh)
*
|
2003-09-18 |
2011-08-10 |
参天制药株式会社 |
经巩膜递送
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7220755B2
(en)
|
2003-11-12 |
2007-05-22 |
Biosensors International Group, Ltd. |
42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
|
ATE534424T1
(de)
*
|
2004-03-19 |
2011-12-15 |
Abbott Lab |
Mehrfache arzneiabgabe aus einem ballon und eine prothese
|
US20070027523A1
(en)
*
|
2004-03-19 |
2007-02-01 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using coated balloon
|
US8431145B2
(en)
|
2004-03-19 |
2013-04-30 |
Abbott Laboratories |
Multiple drug delivery from a balloon and a prosthesis
|
US20100030183A1
(en)
*
|
2004-03-19 |
2010-02-04 |
Toner John L |
Method of treating vascular disease at a bifurcated vessel using a coated balloon
|
ATE410431T1
(de)
*
|
2004-04-14 |
2008-10-15 |
Wyeth Corp |
Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
|
BRPI0510277A
(pt)
*
|
2004-04-27 |
2007-10-30 |
Wyeth Corp |
método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
|
WO2006115509A2
(en)
|
2004-06-24 |
2006-11-02 |
Novartis Vaccines And Diagnostics Inc. |
Small molecule immunopotentiators and assays for their detection
|
JP2008512350A
(ja)
*
|
2004-07-01 |
2008-04-24 |
イェール ユニバーシティ |
標的化され、そして高密度で薬物が負荷されるポリマー性物質
|
WO2006012527A1
(en)
|
2004-07-23 |
2006-02-02 |
Endocyte, Inc. |
Bivalent linkers and conjugates thereof
|
US7901451B2
(en)
*
|
2004-09-24 |
2011-03-08 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method for treating restenosis
|
AU2005294382A1
(en)
*
|
2004-10-04 |
2006-04-20 |
Qlt Usa, Inc. |
Ocular delivery of polymeric delivery formulations
|
US8313763B2
(en)
*
|
2004-10-04 |
2012-11-20 |
Tolmar Therapeutics, Inc. |
Sustained delivery formulations of rapamycin compounds
|
RU2007112787A
(ru)
*
|
2004-10-28 |
2008-12-10 |
Вайет (Us) |
ПРИМЕНЕНИЕ ИНГИБИТОРА mTOR ПРИ ЛЕЧЕНИИ ЛЕЙОМИОМЫ МАТКИ
|
US8637070B2
(en)
*
|
2005-02-09 |
2014-01-28 |
Santen Pharmaceutical Co., Ltd. |
Rapamycin formulations and methods of their use
|
US8663639B2
(en)
*
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
GB0503936D0
(en)
*
|
2005-02-25 |
2005-04-06 |
San Raffaele Centro Fond |
Method
|
JP5289935B2
(ja)
*
|
2005-03-16 |
2013-09-11 |
エンドサイト,インコーポレイテッド |
プテロイン酸およびその結合体の合成と精製
|
CA2602525A1
(en)
*
|
2005-03-21 |
2006-09-28 |
Macusight, Inc. |
Drug delivery systems for treatment of diseases or conditions
|
WO2007032777A2
(en)
|
2005-03-23 |
2007-03-22 |
Abbott Laboratories |
Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
|
JP5271697B2
(ja)
*
|
2005-03-23 |
2013-08-21 |
アボット ラボラトリーズ |
医療装置を介する高親油性薬剤の送達
|
WO2006119569A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Genetic Technologies Limtied |
Methods of enriching fetal cells
|
EP1909794A2
(en)
|
2005-07-20 |
2008-04-16 |
Novartis AG |
Combination of organic compounds
|
RS54088B1
(en)
|
2005-07-25 |
2015-10-30 |
Emergent Products Development Seattle Llc |
B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
|
ES2468240T3
(es)
*
|
2005-08-19 |
2014-06-16 |
Endocyte, Inc. |
Conjugados de ligando de múltiples fármacos
|
WO2007056118A1
(en)
|
2005-11-04 |
2007-05-18 |
Wyeth |
Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
|
CN101355876B
(zh)
|
2005-11-09 |
2012-09-05 |
康宾纳特克斯公司 |
一种适用于眼部给药的组合物
|
US7700614B2
(en)
|
2005-12-14 |
2010-04-20 |
Abbott Laboratories |
One pot synthesis of tetrazole derivatives of rapamycin
|
KR20080077989A
(ko)
*
|
2005-12-20 |
2008-08-26 |
와이어쓰 |
약물의 불순물 조절을 통한 cci-779 제형의 안정성 조절
|
US20070196850A1
(en)
*
|
2006-01-27 |
2007-08-23 |
University Of Washington |
Identification of aging genes through large-scale analysis
|
CA2635797C
(en)
*
|
2006-02-09 |
2015-03-31 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
US7678901B2
(en)
*
|
2006-02-28 |
2010-03-16 |
Wyeth |
Rapamycin analogs containing an antioxidant moiety
|
US7622477B2
(en)
*
|
2006-02-28 |
2009-11-24 |
Cordis Corporation |
Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
|
US8222271B2
(en)
|
2006-03-23 |
2012-07-17 |
Santen Pharmaceutical Co., Ltd. |
Formulations and methods for vascular permeability-related diseases or conditions
|
US7883855B2
(en)
*
|
2006-07-21 |
2011-02-08 |
Abbott Laboratories |
Immunosuppressant drug extraction reagent for immunoassays
|
US20080051691A1
(en)
*
|
2006-08-28 |
2008-02-28 |
Wyeth |
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
|
CN104906087A
(zh)
|
2006-09-13 |
2015-09-16 |
万能医药公司 |
大环内酯化合物及它们的使用方法
|
EP2077819A4
(en)
|
2006-09-28 |
2011-05-25 |
Follica Inc |
METHODS, MATERIALS, AND COMPOSITIONS FOR GENERATING NEW CELLULAR FOLLICLES AND PUSHING HAIR
|
US20080097591A1
(en)
*
|
2006-10-20 |
2008-04-24 |
Biosensors International Group |
Drug-delivery endovascular stent and method of use
|
US8067055B2
(en)
*
|
2006-10-20 |
2011-11-29 |
Biosensors International Group, Ltd. |
Drug-delivery endovascular stent and method of use
|
US20080103584A1
(en)
*
|
2006-10-25 |
2008-05-01 |
Biosensors International Group |
Temporal Intraluminal Stent, Methods of Making and Using
|
US8414525B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414526B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
|
US8425459B2
(en)
|
2006-11-20 |
2013-04-23 |
Lutonix, Inc. |
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
|
US20080276935A1
(en)
|
2006-11-20 |
2008-11-13 |
Lixiao Wang |
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
|
US9737640B2
(en)
|
2006-11-20 |
2017-08-22 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8414909B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8998846B2
(en)
|
2006-11-20 |
2015-04-07 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US9700704B2
(en)
|
2006-11-20 |
2017-07-11 |
Lutonix, Inc. |
Drug releasing coatings for balloon catheters
|
US8414910B2
(en)
|
2006-11-20 |
2013-04-09 |
Lutonix, Inc. |
Drug releasing coatings for medical devices
|
US8430055B2
(en)
|
2008-08-29 |
2013-04-30 |
Lutonix, Inc. |
Methods and apparatuses for coating balloon catheters
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
WO2008101231A2
(en)
|
2007-02-16 |
2008-08-21 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
WO2008109347A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Yale University |
Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
|
CN101678124A
(zh)
|
2007-03-14 |
2010-03-24 |
恩多塞特公司 |
结合配体连接的微管溶素递药缀合物
|
TW200901989A
(en)
|
2007-04-10 |
2009-01-16 |
Wyeth Corp |
Anti-tumor activity of CCI-779 in papillary renal cell cancer
|
JP2008305262A
(ja)
*
|
2007-06-08 |
2008-12-18 |
Konica Minolta Business Technologies Inc |
サーバ及びシンクライアント環境でのプリンタ紹介方法
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
EP3569251A1
(en)
|
2007-06-25 |
2019-11-20 |
Endocyte, Inc. |
Conjugates containing hydrophilic spacer linkers
|
EP2167130A2
(en)
*
|
2007-07-06 |
2010-03-31 |
Trubion Pharmaceuticals, Inc. |
Binding peptides having a c-terminally disposed specific binding domain
|
KR100930167B1
(ko)
*
|
2007-09-19 |
2009-12-07 |
삼성전기주식회사 |
초광각 광학계
|
BRPI0722361B8
(pt)
|
2007-12-19 |
2021-07-27 |
Abbott Lab |
métodos para avaliar a concentração de um fármaco imunossupressor em uma amostra de sangue humano, composição de reagente de extração e kit de teste
|
US20100048912A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
US8685995B2
(en)
*
|
2008-03-21 |
2014-04-01 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
NZ588671A
(en)
|
2008-04-11 |
2012-11-30 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
WO2010021681A2
(en)
*
|
2008-08-18 |
2010-02-25 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
EP2352459A4
(en)
*
|
2008-10-03 |
2013-09-25 |
Elixir Medical Corp |
MACROCYCLIC LACTONE COMPOUNDS AND METHODS OF USE
|
CN102292078A
(zh)
|
2008-11-11 |
2011-12-21 |
得克萨斯大学体系董事会 |
哺乳动物雷帕霉素靶蛋白的抑制
|
EP2393827B1
(en)
|
2009-02-05 |
2015-10-07 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
WO2011053938A1
(en)
|
2009-10-30 |
2011-05-05 |
Ariad Pharmaceuticals, Inc. |
Methods and compositions for treating cancer
|
WO2015161139A1
(en)
|
2014-04-16 |
2015-10-22 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
US20110130711A1
(en)
*
|
2009-11-19 |
2011-06-02 |
Follica, Inc. |
Hair growth treatment
|
US8951595B2
(en)
*
|
2009-12-11 |
2015-02-10 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable molecular architecture for drug-coated balloon
|
US8480620B2
(en)
*
|
2009-12-11 |
2013-07-09 |
Abbott Cardiovascular Systems Inc. |
Coatings with tunable solubility profile for drug-coated balloon
|
US20110144577A1
(en)
*
|
2009-12-11 |
2011-06-16 |
John Stankus |
Hydrophilic coatings with tunable composition for drug coated balloon
|
US20130195919A1
(en)
|
2010-03-05 |
2013-08-01 |
President And Fellows Of Harvard College |
Induced dendritic cell compositions and uses thereof
|
EP2558092B1
(en)
|
2010-04-13 |
2018-06-27 |
Novartis AG |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
SG184311A1
(en)
|
2010-04-16 |
2012-11-29 |
Novartis Ag |
Combination of organic compounds
|
EP2563391B1
(en)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
KR101253399B1
(ko)
|
2010-10-26 |
2013-04-11 |
영남대학교 산학협력단 |
아포지단백질 a-i 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
|
CN106279401A
(zh)
|
2011-03-11 |
2017-01-04 |
贝丝以色列女执事医疗中心 |
Cd40片段及其用途
|
WO2012148846A1
(en)
|
2011-04-25 |
2012-11-01 |
Novartis Ag |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
EP2532740A1
(en)
|
2011-06-11 |
2012-12-12 |
Michael Schmück |
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
|
WO2013013708A1
(en)
|
2011-07-26 |
2013-01-31 |
Fundació Institut D'investigació Biomèdica De Bellvitge |
Treatment of acute rejection in renal transplant
|
US10080805B2
(en)
|
2012-02-24 |
2018-09-25 |
Purdue Research Foundation |
Cholecystokinin B receptor targeting for imaging and therapy
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
EP2841098A4
(en)
|
2012-04-23 |
2016-03-02 |
Allertein Therapeutics Llc |
NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
|
PL2859001T3
(pl)
|
2012-06-08 |
2016-08-31 |
Biotronik Ag |
40-o-podstawiona pochodna estrowa rapamycyny i węglowodoru cyklicznego, kompozycje i metody
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
CN103705925B
(zh)
|
2012-09-29 |
2018-03-30 |
段磊 |
抑制PI3K/AKT/mTOR信号通路的药物组合
|
US9750728B2
(en)
|
2012-09-29 |
2017-09-05 |
Targeted Therapeutics, Llc |
Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
|
WO2014059295A1
(en)
|
2012-10-12 |
2014-04-17 |
The Board Of Regents Of The University Of Texas System |
Use of mtor inhibitors to treat vascular cognitive impairment
|
AU2013331440A1
(en)
|
2012-10-16 |
2015-04-30 |
Endocyte, Inc. |
Drug delivery conjugates containing unnatural amino acids and methods for using
|
EP2914260A1
(en)
|
2012-10-31 |
2015-09-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preventing antiphospholipid syndrome (aps)
|
EP2919759A4
(en)
|
2012-11-14 |
2016-07-20 |
Ohio State Innovation Foundation |
MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
|
WO2014160328A1
(en)
|
2013-03-13 |
2014-10-02 |
The Board Of Regents Of The University Of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
KR20150127720A
(ko)
|
2013-03-14 |
2015-11-17 |
유니버시티 오브 매릴랜드, 발티모어 |
안드로겐 수용체 하향 조절제 및 그의 용도
|
KR102233251B1
(ko)
|
2013-04-03 |
2021-03-26 |
엔-폴드 엘엘씨 |
신규 나노입자 조성물
|
BR112016002970A2
(pt)
|
2013-08-12 |
2017-09-12 |
Tokai Pharmaceuticals Inc |
biomarcadores para o tratamento de distúrbios neoplásicos que usa terapias direcionadas ao androgênio
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
CA3206208A1
(en)
|
2013-12-31 |
2015-07-09 |
Rapamycin Holdings, Llc |
Oral rapamycin nanoparticle preparations and use
|
KR20160110963A
(ko)
|
2014-02-11 |
2016-09-23 |
노파르티스 아게 |
암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
|
CA2943609A1
(en)
|
2014-03-27 |
2015-10-01 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
US10258639B2
(en)
|
2014-05-06 |
2019-04-16 |
Research Development Foundation |
Methods for treating insulin resistance and for sensitizing patients to GLP1 agonist therapy
|
CA2950589A1
(en)
|
2014-06-02 |
2015-12-10 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
EP3193902A4
(en)
|
2014-09-11 |
2018-03-28 |
The Regents of The University of California |
mTORC1 INHIBITORS
|
ES2746105T3
(es)
|
2014-10-08 |
2020-03-04 |
Epigenetics Pharma Llc |
Profármacos de 5-aza-pirimidina sililada útiles para tratar el cáncer
|
WO2017029391A1
(en)
|
2015-08-20 |
2017-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method for treating cancer
|
AU2016315873B2
(en)
|
2015-09-04 |
2022-08-18 |
Primatope Therapeutics Inc. |
Humanized anti-CD40 antibodies and uses thereof
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
BR112018077259A2
(pt)
|
2016-06-30 |
2019-06-18 |
Durect Corporation |
formulações depot
|
HUE056777T2
(hu)
|
2016-12-22 |
2022-03-28 |
Amgen Inc |
Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
|
EA201990127A1
(ru)
|
2016-12-30 |
2020-08-18 |
Дьюрект Корпорейшн |
Депо-препарат
|
JP2020507632A
(ja)
|
2017-02-10 |
2020-03-12 |
マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. |
ラパマイシン類似体
|
ES2871499T3
(es)
|
2017-05-15 |
2021-10-29 |
Bard Inc C R |
Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3644997A1
(en)
|
2017-06-26 |
2020-05-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
|
WO2019012024A1
(en)
|
2017-07-13 |
2019-01-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS FOR INCREASING EXPANSION AND IMMUNOSUPPRESSIVE CAPACITY OF A CD8 + CD45RCBAS TREGS POPULATION / -
|
JP7150823B2
(ja)
|
2017-09-08 |
2022-10-11 |
アムジエン・インコーポレーテツド |
KRas G12Cの阻害剤及びそれを使用する方法
|
AR112834A1
(es)
|
2017-09-26 |
2019-12-18 |
Novartis Ag |
Derivados de rapamicina
|
CR20200578A
(es)
|
2018-05-01 |
2021-02-22 |
Revolution Medicines Inc |
Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
|
CN112368289B
(zh)
|
2018-05-01 |
2024-02-20 |
锐新医药公司 |
作为mtor抑制剂的c26-连接的雷帕霉素类似物
|
US11090304B2
(en)
|
2018-05-04 |
2021-08-17 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7361722B2
(ja)
|
2018-05-04 |
2023-10-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤及び同一物の使用方法
|
EP3790886A1
(en)
|
2018-05-10 |
2021-03-17 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
WO2019232419A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CA3099799A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
AU2019336588B2
(en)
|
2018-06-12 |
2022-07-28 |
Amgen Inc. |
KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
|
EP3826650A4
(en)
|
2018-07-23 |
2022-07-27 |
Enclear Therapies, Inc. |
METHODS OF TREATMENT OF NEUROLOGICAL DISEASES
|
JP2022510573A
(ja)
|
2018-07-23 |
2022-01-27 |
エンクリアー セラピーズ, インク. |
神経障害の治療方法
|
US20220047567A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of neurofibromatosis
|
EP3880266A1
(en)
|
2018-11-14 |
2021-09-22 |
Lutonix, Inc. |
Medical device with drug-eluting coating on modified device surface
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
EP3897852A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3898616A1
(en)
|
2018-12-20 |
2021-10-27 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CA3130083A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
WO2020209828A1
(en)
|
2019-04-08 |
2020-10-15 |
Bard Peripheral Vascular, Inc. |
Medical device with drug-eluting coating on modified device surface
|
AU2020271894A1
(en)
|
2019-04-11 |
2021-12-02 |
Enclear Therapies, Inc. |
Methods of amelioration of cerebrospinal fluid and devices and systems therefor
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
SG11202112855WA
(en)
|
2019-05-21 |
2021-12-30 |
Amgen Inc |
Solid state forms
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020325115A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
Pyridine derivatives as KIF18A inhibitors
|
WO2021055728A1
(en)
|
2019-09-18 |
2021-03-25 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
CA3155857A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER
|
EP4051678A1
(en)
|
2019-10-28 |
2022-09-07 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
EP4051266A1
(en)
|
2019-10-31 |
2022-09-07 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
AU2020379731A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
EP4055028A1
(en)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN114901662A
(zh)
|
2019-11-08 |
2022-08-12 |
锐新医药公司 |
双环杂芳基化合物及其用途
|
US20230192682A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
AU2020381492A1
(en)
|
2019-11-14 |
2022-05-26 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
JP2023509701A
(ja)
|
2020-01-07 |
2023-03-09 |
レヴォリューション・メディスンズ,インコーポレイテッド |
Shp2阻害剤投薬およびがんを処置する方法
|
EP4139299A1
(en)
|
2020-04-24 |
2023-03-01 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
KR20230031926A
(ko)
|
2020-07-15 |
2023-03-07 |
다이호야쿠힌고교 가부시키가이샤 |
종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
KR20230067635A
(ko)
|
2020-09-15 |
2023-05-16 |
레볼루션 메디슨즈, 인크. |
암의 치료에서 ras 억제제로서 인돌 유도체
|
JP2024501280A
(ja)
|
2020-12-22 |
2024-01-11 |
キル・レガー・セラピューティクス・インコーポレーテッド |
Sos1阻害剤およびその使用
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
WO2022235864A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
CN117769554A
(zh)
|
2021-05-28 |
2024-03-26 |
大鹏药品工业株式会社 |
Kras突变蛋白的小分子抑制剂
|
CA3223081A1
(en)
|
2021-07-15 |
2023-01-19 |
Samir Mitragotri |
Compositions and methods relating to cells with adhered particles
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024008799A1
(en)
|
2022-07-06 |
2024-01-11 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of proliferative glomerulonephritis
|
WO2024028433A1
(en)
|
2022-08-04 |
2024-02-08 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the treatment of lymphoproliferative disorders
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|